Profile data is unavailable for this security.
About the company
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
- Revenue in USD (TTM)0.00
- Net income in USD-7.07m
- Incorporated2023
- Employees9.00
- LocationMymd Pharmaceuticals Inc855 N. Wolfe Street, Suite 601BALTIMORE 21205United StatesUSA
- Websitehttps://www.mymd.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 3.80m | 0.00 | -- | 2.14 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 3.83m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Mosaic Immunoengineering Inc | 0.00 | -897.69k | 3.86m | 3.00 | -- | -- | -- | -- | -0.1245 | -0.1245 | 0.00 | -0.8498 | 0.00 | -- | -- | 0.00 | -789.46 | -- | -- | -- | -- | -- | -- | -- | -- | -26.91 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
ProtoKinetix, Inc. | 0.00 | -400.47k | 3.88m | 0.00 | -- | 9.79 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
Enveric Biosciences Inc | 0.00 | -15.11m | 3.95m | 7.00 | -- | 0.5739 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
Trevena Inc | 3.14m | -40.15m | 3.97m | 23.00 | -- | -- | -- | 1.27 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
Genprex Inc | 0.00 | -27.63m | 3.99m | 26.00 | -- | 0.4172 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
Axim Biotechnologies Inc | 85.35k | -5.59m | 4.05m | 6.00 | -- | -- | -- | 47.47 | -0.0249 | -0.0249 | 0.0003 | -0.0268 | 0.0214 | -- | -- | 14,225.00 | -140.13 | -154.34 | -- | -390.73 | -- | -- | -6,548.75 | -36,362.71 | -- | -1.16 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
Theriva Biologics Inc | 0.00 | -19.04m | 4.11m | 21.00 | -- | 0.13 | -- | -- | -1.15 | -1.15 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -32.65 | -36.95 | -37.33 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 4.18m | 9.00 | -- | 0.1846 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
Palisade Bio Inc | 0.00 | -13.49m | 4.21m | 9.00 | -- | 0.3799 | -- | -- | -24.67 | -24.67 | 0.00 | 11.82 | 0.00 | -- | -- | 0.00 | -96.63 | -132.36 | -111.78 | -165.45 | -- | -- | -- | -27,892.32 | -- | -874.31 | 0.00 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
Emmaus Life Sciences Inc | 28.46m | -4.74m | 4.28m | 55.00 | -- | -- | -- | 0.1505 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
Artelo Biosciences Inc | 0.00 | -9.60m | 4.31m | 5.00 | -- | 0.4518 | -- | -- | -3.13 | -3.13 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -66.62 | -- | -70.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
Adial Pharmaceuticals Inc | 0.00 | -11.24m | 4.43m | 4.00 | -- | 0.6936 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Global X Management Co. LLCas of 31 Mar 2024 | 875.93k | 37.96% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 30.35k | 1.32% |
Iroquois Capital Management LLCas of 24 May 2024 | 6.72k | 0.29% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.56k | 0.28% |
UBS Securities LLCas of 31 Mar 2024 | 1.96k | 0.09% |
Bridgecreek Investment Management LLCas of 31 Dec 2023 | 1.00k | 0.04% |
Parallel Advisors LLCas of 31 Mar 2024 | 838.00 | 0.04% |
Group One Trading LPas of 31 Mar 2024 | 459.00 | 0.02% |
Vanguard Global Advisers LLCas of 31 Mar 2024 | 310.00 | 0.01% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 247.00 | 0.01% |